MedTrace Logo

Biofeedback Intervention in Adolescents With Autism Spectrum Disorder

NCT04628715 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-03-30

No results posted yet for this study

Summary

This study consists of two phases, a cross-sectional and a interventional. The cross-sectional phase will provide more insight into the differences in the autonomic functioning between adolescents with autism spectrum disorder and their typically developing peers. During the longitudinal phase, the efficacy of an RSA biofeedback intervention will be examined in adolescents with autism spectrum disorder.

Conditions

Interventions

DEVICE

RSA biofeedback

Biofeedback intervention based on breathing at resonance frequency

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Tine Van Damme, Professor · KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-26
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04628715 on ClinicalTrials.gov